STAT
MAY 15, 2023
At the urging of the Alliance for Pharmacy Compounding, the trade association I lead, the Food and Drug Administration in April 2020 issued temporary guidance allowing traditional compounding pharmacies, within tight regulatory guardrails, to prepare 13 Covid drugs from pure ingredients to meet hospitals’ urgent need.
RX Note
JUNE 5, 2023
Introduction In 2018, the Ministry of Health Malaysia published the Good Compounding Practice as a guidance for compounding practices. NOTE: When compounding a preparation using the contents of an ampoule , care should be taken to withdraw the solution using a filter needle to avoid incorporating glass particles into the compound.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
SEPTEMBER 4, 2023
Consequently, there is a surge in hiring for cybersecurity-related roles including data, automation, security, compliance, risk, and relationships in Q2 2023, reflecting a 34 per cent compound annual growth rate since 2020, reveals the Job Analytics Database of GlobalData.
Eye on FDA
JANUARY 6, 2021
During 2020, FDA was able to approve 53 – not surpassing the 2018 all time record of 59, but certainly an admirable second place. Notably, the 2020 NME approvals included 22 related to oncology, with 2 new GIST treatments, 3 in breast cancer and 2 approvals in prostate cancer. That, however, was not really the case.
Eye on FDA
FEBRUARY 10, 2021
Looking now to a review of enforcement by the Office of Prescription Drug Promotion (OPDP) in 2020, we see a different picture. The collection of letters issued by OPDP during 2020 can be found here. We instead see the same pace as we have the past several years – that is anemic levels of enforcement.
pharmaphorum
DECEMBER 23, 2020
2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”. Merck & Co is already a major player in immunotherapy with its Keytruda (pembrolizumab) and spent $2.75
Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.
Expert insights. Personalized for you.
244 
Let's personalize your content